The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Open accessAbstract
PURPOSE: Preclinical data have demonstrated that BIBW 2992 is a potent irreversible inhibitor of ErbB1 (EGFR/HER1) and mutated ErbB1 receptors including the T790M variant, as well as ErbB2 (HER2). A phase I study of continuous once-daily oral BIBW 2992 was conducted to determine safety, maximum-tolerated dose, pharmacokinetics (PK), food effect, and preliminary antitumor efficacy. PATIENTS AND METHODS: Patients with advanced solid tumors were treated. PK evaluation was performed after the first dose and at steady-state. RESULTS: Fifty-three patients received BIBW 2992 at 10 to 50 mg/d. BIBW 2992 was generally well-tolerated. The most common adverse effects included diarrhea, nausea, vomiting, rash, and fatigue. Dose-limiting toxicities included grade 3 rash (n = 2) and reversible dyspnea secondary to pneumonitis (n = 1). The recommended phase II dose was 50 mg/d. PK was dose proportional with a terminal elimination half-life ranging between 21.3 and 27.7 hours on day 1 and between 22.3 and 67.0 hours on day 27; BIBW 2992 exposure decreased after food intake. Three patients with non-small-cell lung carcinoma (NSCLC; two with in-frame exon 19 mutation deletions) experienced confirmed partial responses (PR) sustained for 24, 18, and 34 months, respectively. Two other patients (esophageal carcinoma and NSCLC) had nonconfirmed PRs. A patient with a PR at 10 mg/d progressed and developed symptomatic brain metastases, which subsequently regressed with an increased dose of 40 mg/d of BIBW 2992. A further seven patients had disease stabilization lasting > or = 6 months. CONCLUSION: Continuous, daily, oral BIBW 2992 is safe and has durable antitumor activity. It is currently being evaluated in phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Administration after a high-fat meal results in an approximately 40% reduction in the area under the time–concentration curve from time 0 to infinity (414 ng · h/ml fed; 676 ng · h/ml fasted)”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [55]
In the citing paper
“We characterized Y764_V765insHH, M766_A767insAI, A767_V769dupASV, D770_N771insNPG, D770_N771insSVD and H773_V774insH using in vitro models and found that cells bearing these mutant EGFR proteins are not inhibited by clinically-achievable doses of gefitinib, erlotinib 12,35,52–54 or the irreversible EGFR inhibitor afatinib 35,55.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Research works printed but not linked: 4
- Solca F, Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 118
- Agus DB, 2006, J Clin Oncol, 24, 97s
- Lewis N, 2006, J Clin Oncol, 24, 143s
- Shih JY, 2009, J Clin Oncol, 27, 410s
Cited by
Sorted by citations
Items 201–300 of 347
Imai, H., Kaira, K., Naruse, I., Hayashi, H., Iihara, H., Kita, Y., Mizusaki, N., Asao, T., Itoh, Y., Sugiyama, T., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3201-9 · Cited by 18
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
Bahleda, R., Hollebecque, A., Varga, A., Gazzah, A., Massard, C., Deutsch, É., Amellal, N., Farace, F., Ould-Kaci, M., Roux, F., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.374 · Cited by 17
Marshall, J. L., Shapiro, G. I., Uttenreuther‐Fischer, M., Ould-Kaci, M., Stopfer, P., & Gordon, M. S. (2013) · Future Oncology · doi:10.2217/fon.12.195 · Cited by 17
Self-citationGunzer, K., Joly, F., Ferrero, J.-., Gligorov, J., de Mont-Serrat, H., Uttenreuther‐Fischer, M., Pelling, K., Wind, S., Bousquet, G., & Misset, J. L. (2016) · SpringerPlus · doi:10.1186/s40064-015-1601-7 · Cited by 17
Self-citationRecent advances in targeted advanced lung cancer therapy in the elderly
Losanno, T., & Gridelli, C. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1348232 · Cited by 16
Sattler, M., Mambetsariev, I., Fricke, J., Tan, T., Liu, S., Vaidehi, N., Pisick, E. P., Mirzapoiazova, T., Rock, A. G., Merla, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051936 · Cited by 16
Scheffler, M., Kobe, C., Zander, T., Nogová, L., Kahraman, D., Thomas, R. K., Neumaier, B., Dietlein, M., & Wolf, J. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.110 · Cited by 16
Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16
Jain, P., Khanal, R., Sharma, A., Yan, F., & Sharma, N. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.983083 · Cited by 17
First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
Liao, B.-C., Lin, C., & Yang, J. C. (2013) · Drugs · doi:10.1007/s40265-013-0020-8 · Cited by 16
Spicer, J. F., Baird, R. D., Suder, A., Cresti, N., Corbacho, J. G., Hogarth, L., Frenkel, E. P., Matsumoto, S., Kawabata, I., Donaldson, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.003 · Cited by 15
Self-citationTargeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice
Bourdeanu, L., & Luu, T. H. (2014) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2014.5.4.2 · Cited by 15
Afatinib in Non-Small Cell Lung Cancer.
Wirth, S. M. (2015) · Europe PMC (PubMed Central) · Cited by 15
Li, L., Zhang, D., Wu, Y., Wang, J., & Ma, F. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188969 · Cited by 14
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Wu, W.-S., & Chen, Y. (2014) · Journal of Personalized Medicine · doi:10.3390/jpm4030297 · Cited by 14
Yu, C.-H., Chou, C., Tu, H.-F., Huang, W.-C., Ho, Y.-Y., Khoo, K., Lee, M., & Chang, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25177 · Cited by 15
Hong, M. H., Heo, S. G., Lee, Y., Kim, H. S., Park, K. U., Kim, H., Ko, Y. H., Chung, I., Min, Y. J., Kim, M. K., et al. (2020) · Cancer · doi:10.1002/cncr.33123 · Cited by 14
Longton, E., Schmit, K., Fransolet, M., Clement, F., & Michiels, C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00432 · Cited by 14
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer
Wittlinger, F., & Laufer, S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1936496 · Cited by 15
Brain Metastases from Non-Small Cell Lung Cancer
Fekrazad, M. H., Sanaei, O., Bauman, J. E., & Jones, D. V. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800896-6.00014-0 · Cited by 14
Davoodi‐Semiromi, A., Hassanzadeh, A., Wasserfall, C. H., Droney, A., & Atkinson, M. A. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9707-y · Cited by 14
Tanaka, H., Taima, K., Tanaka, Y., Itoga, M., Ishioka, Y., Nakagawa, H., Baba, K., Hasegawa, Y., Takanashi, S., & Tasaka, S. (2018) · Medical Oncology · doi:10.1007/s12032-018-1098-3 · Cited by 13
Pharmacology of Tyrosine Kinase Inhibitors
Hulin, A., Gelé, T., Fenioux, C., Kempf, E., Sahali, D., Tournigand, C., & Ollero, M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000395 · Cited by 12
Harbeck, N., Solca, F., & Gauler, T. C. (2013) · Future Oncology · doi:10.2217/fon.13.244 · Cited by 12
Ko, R., Shukuya, T., Imamura, C. K., Tokito, T., Shimada, N., Koyama, R., Yamada, K., Ishii, H., Azuma, K., & Takahashi, K. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-824 · Cited by 11
New advances in targeted therapies for squamous cell carcinoma of the head and neck
Machiels, J., & Schmitz, S. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328341071e · Cited by 12
Khan, F., Ottensmeier, C. H. H., Popat, S., Dua, D., Dorey, N., Ellis, S. H., Szabo, M., Upadhyay, S., Califano, R., Chan, S., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.001 · Cited by 12
Self-citationSartori, G., Belluomini, L., Lombardo, F., Avancini, A., Trestini, I., Vita, E., Tregnago, D., Menis, J., Bria, E., Milella, M., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1776119 · Cited by 12
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer
Wang, D. D., Lee, V. H.-F., Zhu, G., Zou, B., Ma, L., & Yan, H. (2016) · Molecular BioSystems · doi:10.1039/c6mb00038j · Cited by 12
Lin, L., Xie, C., Gao, Z., Chen, X., & Zhong, D. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056341 · Cited by 11
Sun, K., Wang, X., Zhang, H., Lin, G., & Jiang, R. (2024) · Cancer Control · doi:10.1177/10732748241278039 · Cited by 12
Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents
Ma, X., Wang, Z., Li, Y., Wang, Y., & Liu, W. (2024) · Medicinal Research Reviews · doi:10.1002/med.22021 · Cited by 11
Santarpía, M., Altavilla, G., Pitini, V. V., & Rosell, R. (2015) · Future Oncology · doi:10.2217/fon.14.320 · Cited by 11
Treatment of Brain Metastases from HER-2-Positive Breast Cancer: Current Status and New Concepts
Bartolotti, M., Franceschi, E., & Brandes, A. A. (2013) · Future Oncology · doi:10.2217/fon.13.90 · Cited by 12
Chu, Q. S.-C., Sangha, R. S., Hotte, S. J., Sergenson, G., Schnell, D., Chand, V. K., & Hirte, H. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0139-9 · Cited by 11
Tiwari, S. V., Pansare, D. N., Lokwani, D. K., Bhandari, S. V., Kanode, V. V., Tandale, O. V., & Kadam, A. R. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101760 · Cited by 10
He, B., Xu, Y., Ding, V. W., Zhang, H., Zhang, X., & Jablons, D. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s92996 · Cited by 13
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Yokota, T., Bendell, J. C., LoRusso, P. M., Tsushima, T., Desai, V., Kenmotsu, H., Watanabe, J., Ono, A., Murugesan, B. G., Silva, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0102-1 · Cited by 11
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Kunos, C. A., Capala, J., Kohn, E. C., & Ivy, S. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00560 · Cited by 10
Gordon, M. S., Springett, G. M., Su, Y. B., Ould-Kaci, M., Wind, S., Zhao, Y., & LoRusso, P. M. (2015) · Future Oncology · doi:10.2217/fon.15.50 · Cited by 10
Zukin, M. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1590/s0104-42302012000200025 · Cited by 10
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
Kim, D. W. N., Nam, T., Choe, K. S., & Choy, H. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.2.74 · Cited by 10
Skrzypski, M. T., Szymanowska-Narloch, A., & Dziadziuszko, R. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.70116 · Cited by 9
Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer
Berge, E. M., Thompson, C., & Messersmith, W. A. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.011 · Cited by 9
Burotto, M., Ali, S. A., & Coyne, G. O. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.973400 · Cited by 9
Gurtner, K., Ebert, N., Pfitzmann, D., Eicheler, W., Zips, D., Baumann, M. A., & Krause, M. (2014) · Radiation Oncology · doi:10.1186/s13014-014-0261-z · Cited by 9
Ammoun, S., Maze, M. E., Reeves, S., Hilton, D. A., Ercolano, E., Hamemann, P. O., & Belshaw, R. D. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now293.002 · Cited by 9
Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors
Li, X., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908112847 · Cited by 10
Targeted treatments for metastatic esophageal squamous cell cancer
Digklia, A. (2013) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v5.i5.88 · Cited by 9
Bordoni, R. E. (2010) · Therapy · doi:10.2217/thy.10.86 · Cited by 9
Amin, A., Khan, M. A., Shah, S., Ahmad, M., Zafar, M. N., & Hameed, A. (2013) · PubMed · Cited by 9
Tan, Y., Cao, K., Ren, G., Qin, Z., Zhao, D., Li, N., Chen, X., Xia, Y., & Lu, Y. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1610585 · Cited by 9
Research progress on covalent inhibitors targeting alkaline amino acids
Zhao, B., Xu, S., Zhou, S., Jiang, X., Jiang, A., Lei, H., & Zhai, X. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108800 · Cited by 8
Koga, T., Soh, J., Hamada, A., Miyano, Y., Fujino, T., Obata, K., Ohara, S., Nishino, M., Chiba, M., Shimoji, M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100554 · Cited by 8
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8
BIBW 2992 in non-small cell lung cancer
Subramaniam, D. S., & Hwang, J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.557063 · Cited by 8
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
Takata, S., Morikawa, K., Tanaka, H., Itani, H., Ishihara, M., Horiuchi, K., Kato, Y. X., Ikemura, S., Nakagawa, H., Nakahara, Y., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231177021 · Cited by 7
The Diagnosis and Treatment of Brain Metastases in EGFR Mutant Lung Cancer
Minchom, A. R., Yu, K. C., Bhosle, J., & O’Brien, M. (2014) · CNS Oncology · doi:10.2217/cns.14.19 · Cited by 7
The role of afatinib in the management of non-small cell lung carcinoma
Yap, T. A., & Popat, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.832755 · Cited by 7
Self-citationInhibitory Effect of Afatinib on Platelet Activation and Apoptosis
Cao, H., Bhuyan, A. A. M., Umbach, A. T., Bissinger, R., Gawaz, M., & Lang, F. J. W. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484377 · Cited by 7
The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer
Cheung, A. L. M., Xu, W. W., & Li, B. (2015) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s49313 · Cited by 7
Activating Mutations and Targeted Therapy in Cancer
Tuna, M., & Christopher, I. L. (2012) · InTech eBooks · doi:10.5772/48701 · Cited by 8
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.57 · Cited by 7
Drug–diagnostic co-development: challenges and issues
Shimazawa, R., & Ikeda, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1132163 · Cited by 7
Spicer, J. F., Irshad, S., Ang, J. E., Enting, D., Kristeleit, R. S., Uttenreuther‐Fischer, M., Pemberton, K., Pelling, K., Schnell, D., & Bono, J. S. D. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3189-1 · Cited by 7
Self-citationDing, S., Wu, Y., Li, B., Wang, X., Ding, H., Zhan, Z., Shen, J., Qi, R., Gao, Z., Yao, K., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108474 · Cited by 6
Zhou, L. Q., Ren, Y., Wang, X., Miao, D.-L., Lizaso, A., Li, H., Han‐Zhang, H., Qian, J., & Yang, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s206732 · Cited by 6
Vu, T., Hòa, N. T. T., Dao, L., Duong, C., Nguyen, C., Doan, T. T., Nguyen, H. T., Hoang, H. V., Dinh, D., Le, G. K. T., et al. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.5.1581 · Cited by 9
Karikios, D. J., & Boyer, M. J. (2012) · Clinical Investigation · doi:10.4155/cli.12.7 · Cited by 6
Yamaguchi, T., Hayashi, H., Isogai, S., Hayashi, M., Uozu, S., Gotô, Y., Nakanishi, T., Sugiyama, T., Itoh, Y., & Imaizumi, K. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.09.006 · Cited by 6
Zhang, T., Li, Q., Chen, S., Luo, Y., Fan, Y., & Xu, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13581 · Cited by 6
Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs
Ji, Y., Tan, E., Hengelage, T., Quinlan, M., & Hendriks, B. S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2911 · Cited by 5
Hassan, H. A., Abbas, S. H., Beshr, E. A. M., Ezelarab, H. A. A., & Ali, T. F. S. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.217559.1190 · Cited by 5
Afatinib treatment in advanced non-small cell lung cancer.
Hurwitz, J., Scullin, P., & Campbell, L. (2011) · Lung Cancer · doi:10.2147/lctt.s16310 · Cited by 20
Investigational therapies targeting the ErbB family in oesophagogastric cancer
Moorcraft, S. Y., & Chau, I. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.930126 · Cited by 5
Puliafito, I., Esposito, F., Raciti, G., Giuffrida, P., Caltavuturo, C., Colarossi, C., Munaò, S., Sciacca, D., & Giuffrida, D. (2022) · Journal of International Medical Research · doi:10.1177/03000605211058864 · Cited by 5
Chu, J., Zhai, W., Geng, Y., Feng, Y., Wang, J., Li, J., Wang, Y., Zhuang, W.-Y., Che, Y., Li, Y., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110592 · Cited by 5
D’Erasmo, M. P., Smith, W. B., Múñoz, A., Mohandas, P., Au, A. S., Marineau, J., Quadri, L. E. N., Bradner, J. E., & Murelli, R. P. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.102 · Cited by 4
Uğurluer, G., & Özşahin, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.951435 · Cited by 4
HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies
Dey, N., Leyland-Jones, B. R., & De, P. K. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_8 · Cited by 4
Zukin, M. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70190-2 · Cited by 4
Targeted Chemotherapeutics: An Overview of the Recent Progress in Effectual Cancer Treatment
Chaudhury, A., Kulhari, A., & Sheorayan, A. (2013) · Pharmacologia · doi:10.5567/pharmacologia.2013.535.552 · Cited by 4
Modi, S. J., & Kulkarni, V. M. (2018) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.52.4s.112 · Cited by 3
Castellanos, E. H., Rivera, G. A., Wakelee, H. A., & Horn, L. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.005 · Cited by 3
Liu, J., Zhang, H., Zhu, X., Chen, H., Li, X., & Ding, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.636324 · Cited by 3
Biomarkeranalytik aus Sicht des Pathologen
Buettner, R., & Heydt, C. (2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-013-1823-1 · Cited by 3
The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease
Lam, J., & Stewart, J. (2012) · InTech eBooks · doi:10.5772/37901 · Cited by 3
Improving the accuracy of therapy descriptions in clinical trials using a bottom-up approach.
Tong, M., & Taira, R. K. (2012) · PubMed Central · Cited by 3
HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies
Tsang, R. Y., & Finn, R. S. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.04.004 · Cited by 3
Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00001-9 · Cited by 4
Wang, S., Wu, T., Liu, Y., Shi, C., & Fu, Z. (2026) · Cancer Control · doi:10.1177/10732748261452789 · Cited by 2
PI3K–AKT–mTOR inhibitors for the systemic treatment of endometrial cancer
Church, D. N., Koppensteiner, R., Yap, T. A., Fink, D. A., & Dedes, K. J. (2012) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.12.51 · Cited by 2
Self-citationHamada, A., Suda, K., Koga, T., Fujino, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Takemoto, T., Soh, J., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.014 · Cited by 3
Juarez, T., Gill, J. M., Heng, A., Carrillo, J., Wagle, N. A., Nomura, N., Nguyen, M., Truong, J., Dobrawa, L., Sivakumar, W., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae049 · Cited by 2
Thyrosinkinaseinhibitoren in der Onkologie
Zander, T., & Hallek, M. J. (2011) · Der Internist · doi:10.1007/s00108-011-2818-3 · Cited by 2
Drug Monographs: Afatinib and Obinutuzumab
Mancheril, B. G., Waddell, J. A., & Solimando, D. A. (2014) · Hospital Pharmacy · doi:10.1310/hpj4903-237 · Cited by 2
Prim, N., Fore, M., & Mennecier, B. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2014.03.002 · Cited by 2
Arzneimitteltherapiesicherheit in der klinischen Onkologie
Lipp, H. (2015) · Forum · doi:10.1007/s12312-015-1401-6 · Cited by 2
Kotecki, N., Awada, A. H., Bonneterre, J. M., Hebbar, M., Adenis, A., Cortot, A. B., Cousin, S., Clisant, S., Duhamel, A., & Penel, N. (2016) · Pharmaceutical Medicine · doi:10.1007/s40290-016-0138-6 · Cited by 2
Metadata
- Authors
- Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., Uttenreuther-Fischer, M., Stopfer, P., Futreal, A., Calvert, H., de Bono, J. S., & Plummer, R.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- National Health Service (GB)
- From the Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey; Northern Institute for Cancer Research, Newcastle upon Tyne; Boehringer Ingelheim, Bracknell; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; and Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-09-01
- Volume
- 28
- Issue
- 25
- Pages
- 3965-3972
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114095518
- Cited by
- 349
- References
- 34
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 14 · 2022: 4 · 2021: 12 · 2020: 8 · 2019: 12 · 2018: 18 · 2017: 18 · 2016: 33 · 2015: 40 · 2014: 47 · 2013: 42 · 2012: 48
- FWCI
- 33.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- AstraZeneca
- American Society of Clinical Oncology
- Royal Marsden NHS Foundation Trust
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Cancer Research UK
- National Institute for Health and Care Research
- Newcastle University
- Genentech
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- afatinib, irreversible kinase inhibitors, EGFR, HER2, EGF receptor, T790M mutation, advanced solid tumors, non-small cell lung cancer, pharmacokinetics, food effect, safety, maximum tolerated dose, anticancer activity, brain metastases, esophageal cancer
- MeSH terms
- Afatinib, Adult, Aged, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasms, Quinazolines, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
